Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

Overview of attention for article published in Lancet Oncology, December 2012

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 2 news outlets
policy: 2 policy sources
twitter: 9 X users

patent: 2 patents
f1000: 1 research highlight platform
guideline: 2 clinical guideline sources

Readers on

mendeley: 163 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 2 policy documents that reference this research output.

Targeted Therapies for the Management of Ovarian Cancer (Scientific Impact Paper No. 12)

Cited by Royal College of Obstetricians and Gynaecologists (RCOG) on 09 Mar 2022

The Royal College of Obstetricians and Gynaecologists (RCOG) works to improve health care for women everywhere, by setting standards for clinical practice, providing doctors with training and lifelong learning, and advocating for women’s health care worldwide.

Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer: Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91

Cited by National Institute for Health and Care Excellence (NICE) on 27 Sep 2013

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.